Open Access
ARTICLE
Benefit of prophylactic bronchodilator with β2 adrenergic agonist in ischemia-reperfusion-induced lung injury
CHEN-LIANG TSAI1, YU-HUEI LIN2, CHIH-YING CHANGCHIEN3, CHIH-FENG CHIAN1,#,*, CHI-HUEI CHIANG4,#,*
1 Division of Pulmonary and Critical Care, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, 114, Taiwan
2 Post-Baccalaureate Program in Nursing, College of Nursing, Taipei Medical University, Taipei, 110, Taiwan
3 Department of General Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, 114, Taiwan
4 Division of Pulmonary Immunology and Infectious Diseases, Chest Department, Taipei Veterans General Hospital, Taipei, 112, Taiwan
* Address correspondence to: Chi-Huei Chiang, ; Chih-Feng Chian,
# These authors contributed equally to this work
(This article belongs to the Special Issue: Cellular Biomechanics in Health and Diseases)
BIOCELL 2021, 45(5), 1201-1211. https://doi.org/10.32604/biocell.2021.014279
Received 15 September 2020; Accepted 24 February 2021; Issue published 12 July 2021
Abstract
Primary lung graft dysfunction could significantly attribute to ischemia-reperfusion lung injury (IRLI) during
transplantation surgery. β2-adrenergic agonists were one of the bronchodilators that had been well-established in the
management of asthma and chronic obstructive pulmonary disease (COPD) with anti-inflammatory potency. By
applying the model of isolated rat lung, we evaluated the efficacy of short-acting β2-agonist inhalation to ameliorate
ischemia-reperfusion damage. The experiment protocol was 180 min of global ischemia and then reperfusion for
60 min. In the β2-agonist inhalation group, aerosolized albuterol was administrated prior ischemia procedure.
Increased weight ratios of wet to dry lung and microvascular permeability were characterized in the IRLI group. In
contrast, pre-inhaled β2-agonist significantly mitigated the severity of pulmonary edema. Bronchoalveolar lavage from
the β2-agonist group presented decreased leukocyte counts and cytokines production, including interleukin-1β
(IL-1β), tumor necrosis factor-α (TNF-α), and macrophage inflammatory protein 2 (MIP-2). Devastating oxidative
stress was widely recognized during the ischemia-reperfusion process, while β2-agonist pretreatment revealed subsided
H2O2, myeloperoxidase (MPO), and the cleavage of caspase-3. Western blotting from lung homogenates identified the
blockade of NF-κB and MAPK activation in the β2-agonist inhalation group. Currently, there was no specific
pharmacotherapy in IRLI management. Our results elucidated the protective effect of β2-agonist bronchodilator
against ischemia-reperfusion induced oxidative stress, inflammation reaction, and pulmonary edema.
Keywords
Cite This Article
TSAI, C., LIN, Y., CHANGCHIEN, C., CHIAN, C., CHIANG, C. (2021). Benefit of prophylactic bronchodilator with β2 adrenergic agonist in ischemia-reperfusion-induced lung injury.
BIOCELL, 45(5), 1201–1211. https://doi.org/10.32604/biocell.2021.014279